Early influenza circulation in South Korea has triggered a public health alert as outpatient clinics record influenza-like illness rates nearly double the national epidemic threshold. According to the Korea Disease Control and Prevention Agency (KDCA), the rate reached 25.3 per 1,000 outpatients for the week ending September 5, prompting health authorities to prepare an earlier-than-usual flu advisory while the national vaccination rollout remains weeks away.
Early Flu Surge Collides With Respiratory Virus Spread
South Korea’s seasonal influenza outbreak has arrived more than a month earlier than last year. Data released by the KDCA for the first week of September shows influenza-like illness at 25.3 cases per 1,000 outpatients, significantly surpassing the epidemic baseline of 12.9 per 1,000 and climbing from 13.3 cases recorded at the end of August. Health officials noted that last year the seasonal advisory was issued on October 17, but the sharp acceleration in autumn cases is forcing an earlier warning across schools and family households.
At the same time, COVID-19 continues to circulate alongside influenza. The KDCA reported a SARS-CoV-2 detection rate of 16.3% among respiratory infection samples for the same September week, with hospitalized patients reaching 193—a more than threefold increase over a four-week period. This simultaneous circulation of multiple respiratory pathogens places heavy pressure on high-risk groups, particularly young children in daycare or school settings and elderly populations with diminished immune responses.
National Vaccination Schedule and Immunity Gaps
The state-sponsored influenza vaccination program is scheduled to begin rolling out by age group starting September 21 and continuing through October. Because the viral spread has accelerated ahead of these inoculation dates, public health specialists emphasize targeted immune support and hygiene measures during the intervening window. Seasonal drops in ambient temperature naturally suppress the functional efficiency of white blood cells, including T cells, B cells, and natural killer (NK) cells, increasing susceptibility to viral entry during seasonal transitions.
Research Findings on Red Ginseng and Immune Response
To evaluate adjunct strategies for bolstering immune defenses ahead of vaccination, researchers have examined the pharmacological effects of Korean red ginseng, which is officially recognized by the Ministry of Food and Drug Safety for supporting immune function, fatigue recovery, and blood circulation.
In animal studies where subjects were administered 100 mg/kg of red ginseng daily for 15 days prior to receiving a pneumococcal vaccine and subsequent bacterial challenge, the group receiving red ginseng demonstrated a roughly 25% increase in antibody generation compared to subjects receiving the vaccine alone. Survival rates in the red ginseng-treated group reached 100%, whereas control groups receiving physiological saline recorded a 50% survival rate, alongside marked reductions in inflammatory cytokines such as TNF-alpha and IL-1beta.
Utilizing bone marrow-derived macrophages infected with influenza A and treated with red ginseng, the researchers observed enhanced destruction of infected cells and a significant decrease in viral protein expression. The findings confirmed that red ginseng activates the ZBP1-dependent cell death pathway to clear infected cells. In animal models, normal mice treated with red ginseng prior to influenza A exposure showed reduced lung tissue damage and substantially higher survival rates compared to untreated infected controls.
Public Health Outlook and Prevention Guidelines
With national flu vaccination campaigns set to begin on September 21, health authorities recommend that families complete their scheduled inoculations according to the age-tiered timeline set by the KDCA. While botanical supplements such as red ginseng show measurable potential in laboratory and animal models for enhancing immune cell activity and vaccine response, medical professionals stress that vaccination remains the primary defense against severe disease and hospitalization during the autumn and winter respiratory season.